New drug combo targets hard-to-treat lung cancer in chinese patients
NCT ID NCT05374603
First seen Jan 24, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a change in the MET gene. About 47 adults in China with this specific type of lung cancer will receive the treatment. The main goal is to see how long the cancer stays under control without growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100021, China
-
Research Site
Beijing, 100039, China
-
Research Site
Beijing, CN-100730, China
-
Research Site
Changsha, 410011, China
-
Research Site
Chongqing, 400010, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310009, China
-
Research Site
Jinan, 250021, China
-
Research Site
Kunming, 650118, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Ningbo, 315100, China
-
Research Site
Shanghai, 200030, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.